Dosage of Foam for Delivering Consumer Desired Dosage Volume, Surfactant Amount, and Scalp Health Agent Amount in an Optimal Formulation Space

• US 20180110696A1
• Filed: 10/20/2017
• Published: 04/26/2018
• Est. Priority Date: 10/21/2016
• Status: Active Grant

• Current Assignee: The Procter & Gamble Company
• Original Assignee: The Procter & Gamble Company
• Inventors: JOHNSON, Eric Scott, Thompson, Todd Ryan, Mullen, Sarah Elizabeth, Torres Rivera, Jazmin Veronica
• Granted Patent: US 10,888,505 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2800/5424 anionic
• CPC Class Codes: A61K 2800/58 Metal complex; Coordination compounds
• CPC Class Codes: A61K 2800/596 Mixtures of surface active compounds
• CPC Class Codes: A61K 2800/87 Application Devices; Containers; Packaging
• CPC Class Codes: A61K 8/046 Aerosols; Foams
• CPC Class Codes: A61K 8/27 Zinc; Compounds thereof
• CPC Class Codes: A61K 8/4913 having five membered rings, e.g. pyrrolidone carboxylic acid
• CPC Class Codes: A61K 8/4926 having six membered rings
• CPC Class Codes: A61K 8/4933 having sulfur as an exocyclic substituent, e.g. pyridinethione
• CPC Class Codes: A61Q 5/006 Antidandruff preparations
• CPC Class Codes: A61Q 5/02 Preparations for cleaning the hair

Abstract

Described herein is a dosage of foam including from about 7.5 cm³ to about 70 cm³. The foam includes from about 0.5 g to about 4 g of a detersive surfactant; from about 0.001 g to about 4 g propellant; a foam density of from about 0.05 g/cm³ to about 0.35 g/cm³; a bubble size distribution having an R₃₂ of from about 5 μm to about 100 μm; from about 0.001 g to about 2.45 g of a scalp health agent; a β value of from about 0.0075 g/cm³ to about 0.1575 g/cm³; and a β′ value of from about 0.00005 g/cm³ to about 0.035 g/cm³.

Claims

1. ) A dosage of foam comprising:

a. from about 7.5 cm³ to about 70 cm³ of the foam;

wherein the foam comprises;

viii. from about 0.5 g to about 4 g of a detersive surfactant by weight of the foam;

ix. from about 0.001 g to about 4 g propellant by weight of the foam;

x. a foam density of from about 0.05 g/cm³ to about 0.35 g/cm³;

xi. a bubble size distribution comprising an R₃₂ of from about 5 μ

m to about 100 μ

m;

xii. from about 0.001 g to about 2.45 g of a scalp health agent;

xiii. a β

value of from about 0.0075 g/cm³ to about 0.1575 g/cm³; and

xiv. a β

′

value of from about 0.00005 g/cm³ to about 0.035 g/cm³.

2. ) The dosage of foam of claim 1, wherein the β

value is from about 0.0200 g/cm³ to about 0.1575 g/cm³.

3. ) The dosage of foam of claim 1, wherein the β

value is from about 0.0300 g/cm³ to about 0.1100 g/cm³.

4. ) The dosage of foam of claim 1, wherein the β

value is from about 0.0300 g/cm³ to about 0.0700 g/cm³.

5. ) The dosage of foam of claim 1, wherein the β

′

value is from about 0.00013 g/cm³ to about 0.028 g/cm³.

6. ) The dosage of foam of claim 1, wherein the β

′

value is from about 0.00025 g/cm³ to about 0.014 g/cm³.

7. ) The dosage of foam of claim 1, wherein the bubble size distribution comprises an R₃₂ of from about 10 μ

m to about 60 μ

m.

8. ) The dosage of foam of claim 1, wherein the dosage of foam comprises from about 0.005 g to about 1.960 g of the scalp health agent.

9. ) The dosage of foam of claim 1, wherein the dosage of foam comprises from about 0.0075 g to about 0.980 g of the scalp health agent.

10. ) The dosage of foam of claim 1, wherein the scalp health agent is an anti-dandruff agent selected from the group consisting of zinc pyrithione, piroctine olamine, climbazole, and mixtures thereof.

11. ) The dosage of foam of claim 1, wherein the volume of the dosage of foam is from about 10 g/cm³ to about 70 g/cm³.

12. ) The dosage of foam of claim 1, wherein the volume of the dosage of foam is from about 20 g/cm³ to about 70 g/cm³.

13. ) The dosage of foam of claim 1, wherein the foam density is from about from about 0.055 g/cm³ to about 0.35 g/cm³.

14. ) The dosage of foam of claim 1, wherein the foam density is from about 0.125 g/cm³ to about 0.35 g/cm³.

15. ) The dosage of foam of claim 1, wherein the foam density is from about 0.125 g/cm³ to about 0.275 g/cm³.

16. ) The dosage of foam of claim 1, wherein the foam density is from about 0.125 g/cm³ to about 0.25 g/cm³.

17. ) The dosage of foam of claim 1, wherein the detersive surfactant is an anionic surfactant.

18. ) The dosage of foam of claim 1, wherein the dosage of foam comprises from about 0.5 g to about 3 g of a detersive surfactant by weight of the foam.

19. ) The dosage of foam of claim 1, wherein the dosage of foam comprises from about 0.75 g to about 1.75 g of a detersive surfactant by weight of the foam.

20. ) A dosage of foam comprising:

a. from about 7.5 cm³ to about 70 cm³ of the foam;

wherein the foam comprises;

viii. from about 0.5 g to about 4 g of a detersive surfactant by weight of the foam;

ix. from about 0.00005 g to about 0.25 g of a cationic deposition polymer by weight of the foam;

x. a foam density of from about 0.05 g/cm³ to about 0.35 g/cm³;

xi. a bubble size distribution comprising an R₃₂ of from about 5 μ

m to about 100 μ

m;

xii. from about 0.001 g to about 2.45 g of a scalp health agent;

xiii. a β

value of from about 0.0075 g/cm³ to about 0.1575 g/cm³; and

xiv. a β

′

value of from about 0.00005 g/cm³ to about 0.035 g/cm³.